Open-label study to assess efficacy and safety of a single dose (i.v.) of NMA78 in patients with Dementia with Lewy Bodies (DLB) or Alzheimer's Disease (AD) and healthy volunteers (HV)
Latest Information Update: 25 Sep 2018
At a glance
- Drugs NMA 78 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Diagnostic use
- Sponsors Nihon Medi-Physics
- 03 Jun 2016 New trial record